The 13D Report
The 13D Report
Shareholder activism
⌘K
Signup free
activistletters

Starboard Value Sees Kenvue (KVUE) Undervalued, Urges Stronger Execution and Margin Recovery to Unlock Shareholder Value

Summary

Starboard’s October 2024 Kenvue presentation argues that the company owns one of the strongest consumer health brand portfolios (Tylenol, Band-Aid, Listerine, Neutrogena, etc.) but trades at the lowest valuation multiple among peers despite defensible categories and attractive end markets. While self-care and essential health segments are performing well, Skin Health & Beauty has underperformed due to weak execution and legacy neglect under J&J ownership, dragging down consolidated growth and margins. Starboard believes Kenvue can revitalize this segment through stronger marketing, innovation, and social media-driven strategies—similar to CeraVe’s success—and restore margins to peer levels. With consistent execution, the firm sees Kenvue’s valuation multiple rising toward peers, making the stock a compelling opportunity with asymmetric upside.

Company Name: KENVUE INC.
Symbol: KVUE
Filing Date: Oct-22-2024
Filer Name: STARBOARD VALUE LP

Download Presentation
Starboard Value Kenvue - Oct-22-2024.pdf
3 MB
download-circle

Source:

https://www.starboardvalue.com/wp-content/uploads/2024_Active-Passive_Investor_Summit_-_Kenvue_Inc.pdf

Member discussion

More like this

STAAR Surgical (STAA): Broadwood Partners Urges Shareholders to Reject Alcon Merger Over Governance and Valuation Concerns

Summary Broadwood Partners’ presentation argues that STAAR Surgical’s sale to Alcon is ill-timed, flawed, and undervalued. It claims STAAR’

Khrom Capital Pushes Acadia Healthcare (ACHC) Board to Pursue Sale, Slams Entrenched Leadership and Poor Capital Allocation

Summary Khrom Capital, owning 5.5% of Acadia Healthcare, criticized the company’s decade-long underperformance, poor capital allocation, and entrenched

STAAR Surgical (STAA): Broadwood Capital Urges Shareholders to Reject Alcon Merger, Highlighting Governance Conflicts and Poor Timing

Summary Broadwood Capital, owning 27.5% of STAAR Surgical, urged shareholders to vote against the proposed $28-per-share sale to Alcon,

Al Hartman Presses Silver Star Properties REIT (SLVS) Holders: Reject Current Board, Back Liquidation Plan Amid Alleged Misconduct and Value Destruction

Summary Al Hartman’s Hartman Shareholder Alliance urges Silver Star investors to vote the BLUE proxy as a “last chance”

Broadwood Partners Challenges STAAR Surgical (STAA) Sale to Alcon, Citing Inopportune Timing, Governance Issues, and Undervaluation

Summary Broadwood Partners, STAAR Surgical’s largest shareholder with a 27.5% stake, urged stockholders to vote against the proposed

Yunqi Capital Challenges STAAR Surgical (STAA)–Alcon Deal, Citing Undervaluation, Weak China Outlook Assumptions, and Governance Failures

Summary Yunqi Capital, a 5.1% shareholder of STAAR Surgical, announced it will vote against the company’s proposed $28